ClinicalTrials.govpublic full text
Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer
breast cancer, hki-272 (neratinib), temsirolimus (cci-779), her2-amplified, triple-negative, invasive adenocarcinoma, 10-005, nerlynx, pb-272, interventional, phase1, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 888078
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.